FDA Grants Priority Review to Priovant's Brepocitinib for Dermatomyositis

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brepocitinib, a treatment for dermatomyositis developed by Priovant Therapeutics. The regulatory agency granted the application Priority Review status, setting a PDUFA target action date for the third quarter of 2026. If approved, brepocitinib would become the first targeted therapy available for patients with this rare inflammatory condition. The submission is supported by positive data from the Phase 3 VALOR trial, which demonstrated consistent efficacy over a 52-week period. This milestone is particularly significant for Priovant’s parent companies, Roivant Sciences and Pfizer, as it validates their clinical pipeline. The accelerated review timeline highlights the potential for brepocitinib to address a major unmet medical need in the biotechnology sector.